Literature DB >> 7947529

Early abortion induction by a combination of mifepristone and oral misoprostol: a comparison between two dose regimens of misoprostol and their effect on blood pressure.

H el-Refaey1, A Templeton.   

Abstract

OBJECTIVES: 1. To investigate the efficacy of 800 micrograms misoprostol (a PGE1 analogue) when administered to women pretreated with mifepristone for early pregnancy termination. 2. To establish means of minimising gastrointestinal side effects by comparing two different misoprostol regimens. The impact of these regimens on blood pressure was investigated in a subgroup of patients.
DESIGN: A randomised study of 150 women of 56 days gestation, or less, allocated to receive oral misoprostol either in a single dose of 800 micrograms or as two doses of 400 micrograms administered sequentially 2 h apart; in each case misoprostol was administered 36 to 48 h after receiving mifepristone 200 mg orally. MAIN OUTCOMES: Complete abortion rates, the frequency and severity (patients' perception) of gastrointestinal side effects, and blood pressure changes in response to prostaglandin administration.
RESULTS: The overall success rate was 93%. Seventy-one (95%) women who received a single dose of misoprostol and sixty-nine (92%) who received the sequential dose aborted completely. There were two ongoing pregnancies in the first group (2.5%) and three (4%) in the second. The overall ongoing pregnancy rate was 3%. The incidence of diarrhoea was significantly lower for women receiving the sequential dose, and no significant differences were found in the incidence of the other gastrointestinal side effects. The only noted significant change in blood pressure was in diastolic pressure 4 h after the administration of the higher dose of prostaglandin, but this was slight.
CONCLUSIONS: The combination of mifepristone and oral misoprostol provides an alternative method to inducing abortion of pregnancies of up to eight weeks gestation. Patients receiving the single dose of 800 micrograms were more troubled by diarrhoea than those on the sequential regimen. The ongoing pregnancy rate was higher than previously reported with vaginal or parenteral administration of prostaglandin.

Entities:  

Keywords:  Abortion, Drug Induced; Abortion, Induced; Biology; Bleeding; Blood Pressure; Comparative Studies; Developed Countries; Diarrhea; Diseases; Endocrine System; Europe; Family Planning; Fertility Control, Postconception; Hemic System; Hormone Antagonists; Hormones; Nausea; Northern Europe; Physiology; Prostaglandins; Prostaglandins, Synthetic; Ru-486; Signs And Symptoms; Studies; United Kingdom; Vomiting

Mesh:

Substances:

Year:  1994        PMID: 7947529     DOI: 10.1111/j.1471-0528.1994.tb11948.x

Source DB:  PubMed          Journal:  Br J Obstet Gynaecol        ISSN: 0306-5456


  6 in total

1.  Medical abortion: what does the research tell us?

Authors:  L E Ferris; A S Basinski
Journal:  CMAJ       Date:  1996-01-15       Impact factor: 8.262

Review 2.  A risk-benefit assessment of oxytocics in obstetric practice.

Authors:  M Winkler; W Rath
Journal:  Drug Saf       Date:  1999-04       Impact factor: 5.606

Review 3.  Medical methods for first trimester abortion.

Authors:  Jing Zhang; Kunyan Zhou; Dan Shan; Xiaoyan Luo
Journal:  Cochrane Database Syst Rev       Date:  2022-05-24

Review 4.  Ergot alkaloids. Current status and review of clinical pharmacology and therapeutic use compared with other oxytocics in obstetrics and gynaecology.

Authors:  A N de Groot; P W van Dongen; T B Vree; Y A Hekster; J van Roosmalen
Journal:  Drugs       Date:  1998-10       Impact factor: 9.546

Review 5.  Medical methods for first trimester abortion.

Authors:  Regina Kulier; Nathalie Kapp; A Metin Gülmezoglu; G Justus Hofmeyr; Linan Cheng; Aldo Campana
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

6.  Medical termination for pregnancy in early first trimester (≤ 63 days) using combination of mifepristone and misoprostol or misoprostol alone: a systematic review.

Authors:  Ferid A Abubeker; Antonella Lavelanet; Maria I Rodriguez; Caron Kim
Journal:  BMC Womens Health       Date:  2020-07-07       Impact factor: 2.809

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.